Hill-Rom Holdings, Inc. (HRC) Receives Average Rating of “Buy” from Brokerages

Hill-Rom Holdings, Inc. (NYSE:HRC) has earned a consensus recommendation of “Buy” from the twelve research firms that are currently covering the company, MarketBeat.com reports. Six analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $92.33.

A number of equities research analysts have issued reports on the company. Zacks Investment Research downgraded Hill-Rom from a “buy” rating to a “hold” rating in a research report on Friday. Goldman Sachs assumed coverage on Hill-Rom in a research report on Wednesday. They set a “neutral” rating and a $85.00 price target for the company. ValuEngine raised Hill-Rom from a “hold” rating to a “buy” rating in a research report on Friday, March 2nd. Needham & Company LLC reissued a “buy” rating on shares of Hill-Rom in a research report on Friday, January 26th. Finally, KeyCorp reissued a “buy” rating and set a $97.00 price target on shares of Hill-Rom in a research report on Thursday, January 18th.

How to Become a New Pot Stock Millionaire

Several hedge funds and other institutional investors have recently modified their holdings of HRC. New York State Common Retirement Fund boosted its position in shares of Hill-Rom by 1.5% in the third quarter. New York State Common Retirement Fund now owns 167,962 shares of the medical technology company’s stock worth $12,429,000 after buying an additional 2,500 shares during the period. Ameriprise Financial Inc. boosted its position in shares of Hill-Rom by 66.9% in the third quarter. Ameriprise Financial Inc. now owns 325,479 shares of the medical technology company’s stock worth $24,085,000 after buying an additional 130,461 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Hill-Rom in the third quarter worth about $348,000. Nordea Investment Management AB boosted its position in shares of Hill-Rom by 13.4% in the third quarter. Nordea Investment Management AB now owns 27,134 shares of the medical technology company’s stock worth $2,008,000 after buying an additional 3,196 shares during the period. Finally, Great West Life Assurance Co. Can boosted its position in shares of Hill-Rom by 5.8% in the third quarter. Great West Life Assurance Co. Can now owns 39,533 shares of the medical technology company’s stock worth $2,894,000 after buying an additional 2,179 shares during the period. 82.50% of the stock is owned by institutional investors.

Hill-Rom stock traded down $1.73 during trading on Friday, hitting $84.45. The company’s stock had a trading volume of 224,785 shares, compared to its average volume of 406,898. The firm has a market capitalization of $5,588.39, a P/E ratio of 21.88, a PEG ratio of 1.36 and a beta of 0.97. Hill-Rom has a 1-year low of $69.47 and a 1-year high of $91.11. The company has a current ratio of 1.75, a quick ratio of 1.29 and a debt-to-equity ratio of 1.39.

Hill-Rom (NYSE:HRC) last posted its quarterly earnings results on Friday, January 26th. The medical technology company reported $0.92 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.79 by $0.13. Hill-Rom had a return on equity of 20.24% and a net margin of 7.14%. The firm had revenue of $669.70 million during the quarter, compared to the consensus estimate of $670.00 million. During the same quarter in the previous year, the business earned $0.75 earnings per share. The firm’s quarterly revenue was up 5.1% compared to the same quarter last year. equities analysts predict that Hill-Rom will post 4.62 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Friday, March 30th. Stockholders of record on Friday, March 23rd were given a $0.20 dividend. This is an increase from Hill-Rom’s previous quarterly dividend of $0.18. The ex-dividend date of this dividend was Thursday, March 22nd. This represents a $0.80 annualized dividend and a dividend yield of 0.95%. Hill-Rom’s dividend payout ratio is presently 20.73%.

ILLEGAL ACTIVITY NOTICE: “Hill-Rom Holdings, Inc. (HRC) Receives Average Rating of “Buy” from Brokerages” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/08/hill-rom-holdings-inc-hrc-receives-average-rating-of-buy-from-brokerages.html.

Hill-Rom Company Profile

Hill-Rom Holdings, Inc is a global medical technology company. The Company partners with health care providers across care settings, by focusing on patient care solutions that improve clinical and economic outcomes in five core areas: advancing mobility, wound care and prevention, patient monitoring and diagnostics, surgical safety and efficiency and respiratory health.

Analyst Recommendations for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply